AC Immune SA Business Summary

AC Immune SA (ACIU) is a clinical-stage biopharmaceutical leader specializing in precision medicine for neurodegenerative diseases, primarily generating revenue through high-value strategic licensing and collaboration agreements with industry giants such as Takeda, Eli Lilly, and Janssen (Johnson & Johnson). The company’s business model is anchored by its proprietary SupraAntigen and Morphomer technology platforms, which fuel a diversified pipeline of active immunotherapies (vaccines), monoclonal antibodies, and small molecules. These assets are categorized into two primary segments: therapeutics, targeting misfolded proteins like Amyloid-beta, Tau, and alpha-synuclein, and diagnostics, which include first-in-class PET tracers for early disease detection. Within the competitive landscape, AC Immune contends with players like Denali Therapeutics, Biogen, and Prothena; however, it distinguishes itself by pioneering a "precision prevention" approach, utilizing vaccines to trigger endogenous antibody production, a strategy that offers potential cost and administration advantages over the passive monoclonal antibody treatments favored by larger peers. The company was co-founded in 2003 by a distinguished scientific team led by CEO Prof. Andrea Pfeifer, Ph.D., formerly the Head of the Nestlé Research Centre, alongside experts such as Prof. Claude Nicolau and Dr. Fred Van Leuven. The current executive leadership includes CFO Christopher Roberts, who transitioned from the interim role in early 2024, and Chief Technical Operations Officer Piergiorgio Donati, who oversees the scaling of the company’s complex biologic and small-molecule manufacturing. The leadership is further bolstered by EVP of Development Günther Staffler and EVP of AI and Information Systems Mark Danton. AC Immune is backed by a sophisticated investor base, including the Biotechnology Value Fund (BVF), dievini Hopp BioTech Holding, and strategic partner Eli Lilly. The Board of Directors features prominent figures such as Monika Bütler and Renée Aguiar-Lucander, ensuring robust governance as the firm advances its late-stage clinical candidates toward potential commercialization.